The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: A case series

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 2, 2012, Pages 159-165

  Sandhu, A ^a   Alameel, T ^b   Dale, C H ^a   Levstik, M ^a   Chande, N ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN; INFLIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ANTIBODY TITER; ARTICLE; AUTOIMMUNE HEPATITIS; BILE DUCT ATRESIA; CADAVER DONOR; CLINICAL ARTICLE; COLITIS; COLON BIOPSY; COLON RESECTION; COLONOSCOPY; COLORECTAL CARCINOMA; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; EVENING DOSAGE; FEMALE; HUMAN; HUMAN TISSUE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; MORNING DOSAGE; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862582233     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05141.x     Document Type: Article

References (52)

1. Peyrin-Biroulet L, Deltenre P, de Suray N, et al,. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6: 644-53. (Pubitemid 351783447)
2. Lal S, Steinhart AH,. Infliximab for ulcerative colitis following liver transplantation. Eur J Gastroenterol Hepatol 2007; 19: 277-80.
3. Harvey RF, Bradshaw JM,. A simple index of Crohn's disease activity. Lancet 1980; 315: 514.
4. Hanauer SB, Feagan BG, Lichtenstein GR, et al,. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002; 359: 1541-9. (Pubitemid 34621118)
5. Rutgeerts P, Sandborn WJ, Feagan BG, et al,. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76. (Pubitemid 41770166)
6. Adami J, Gäbel H, Lindelöf B, et al,. Cancer risk following organ transplantation: A nationwide cohort study in Sweden. Br J Cancer 2003; 89: 1221-7. (Pubitemid 37363407)
7. Olaison G, Sjodahl R, Tagesson C,. Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation. Gut 1990; 31: 325-8. (Pubitemid 20093672)
8. Baumgart DC, Macdonald JK, Feagan B,. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev 2008; 16: CD007216.
9. McSharry K, Dalzell AM, Leiper K, et al,. Systematic review: the role of tacrolimus in the management of Crohn's disease. Aliment Pharmacol Ther 2011; 34: 1282-94.
10. McDonald JW, Feagan BG, Jewell D, et al,. Cyclosporine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2005; 18: CD000297.
11. Shibolet O, Regushevskaya E, Brezis M, et al,. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005; 1: CD004277.
12. García-Lõpez S, Gomollõn-García F, Pérez-Gisbert J,. Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review. Gastroenterología y Hepatología 2005; 28: 607-14. (Pubitemid 43117349)
13. Benson A, Barrett T, Sparberg M, et al,. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflamm Bowel Dis 2008; 14: 7-12. (Pubitemid 351196862)
14. Fellermann K, Steffen M, Stein J, et al,. Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14: 171-6. (Pubitemid 30088293)
15. Timmer A, McDonald JW, Macdonald JK,. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007; 1: CD000478.
16. Sandborn W, Sutherland L, Pearson D, et al,. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database of Systematic Reviews 2000; 2: CD000545.
17. Maser EA, Deconda D, Lichtiger S, et al,. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol 2008; 6: 1112-6.
18. Cheifetz A, Smedley M, Martin S, et al,. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98: 1315-24. (Pubitemid 36741529)
19. Vultaggio A, Matucci A, Nencini F, et al,. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010; 65: 657-61.
20. Hastings R, Ding T, Butt S, et al,. Neutropenia in patients receiving anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken) 2010; 62: 764-9.
21. Galloway JB, Hyrich KL, Mercer LK, et al,. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70: 1810-4.
22. Slifman NR, Gershon SK, Lee JH, et al,. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003; 48: 319-24. (Pubitemid 36277998)
23. Nelson DR, Lim HL, Marousis CG, et al,. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci 1997; 42: 2487-94. (Pubitemid 28103785)
24. Pasquetto V, Wieland SF, Uprichard SL, et al,. Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures. J Virol 2002; 76: 5646-53. (Pubitemid 34517915)
25. Wendling D, Auge B, Bettinger D, et al,. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 2005; 64: 788-9. (Pubitemid 40559316)
26. Ostuni P, Botsios C, Punzi L, et al,. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003; 62: 686-7. (Pubitemid 36760576)
27. Mohan N, Edwards ET, Cupps TR, et al,. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001; 44: 2862-9. (Pubitemid 34016206)
28. Simsek I, Erdem H, Pay S, et al,. Optic neuritis occurring with anti-tumor necrosis factor alpha therapy. Ann Rheum Dis 2007; 66: 1255-8. (Pubitemid 47309747)
29. Shin IS, Baer AN, Kwon HJ, et al,. Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum 2006; 54: 1429-34.
30. Eguren C, Díaz B, Daudén E, et al,. Peripheral neuropathy in two patients with psoriasis in treatment with infliximab. Muscle Nerve 2009; 40: 488-9.
31. Kwon HJ, Coté TR, Cuffe MS, et al,. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138: 807-11.
32. Khasnis AA, Calabrese LH,. Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk. Semin Arthritis Rheum 2010; 40: 147-63.
33. Elliott MJ, Maini RN, Feldmann M, et al,. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344: 1125-8.
34. Ramos-Casals M, Brito-Zerõn P, Muñoz S, et al,. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007; 86: 242-51. (Pubitemid 47067483)
35. Williams EL, Gadola S, Edwards CJ,. Anti-TNF-induced lupus. Rheumatology (Oxford) 2009; 48: 716-20.
36. Bewtra M, Lewis JD,. Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. Expert Rev Clin Immunol 2010; 6: 621-31.
37. Baecklund E, Iliadou A, Askling J, et al,. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006; 54: 692-701.
38. Askling J, Fored CM, Baecklund E, et al,. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1414-20. (Pubitemid 41623850)
39. Wolfe F, Michaud K,. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007; 56: 1433-9. (Pubitemid 46764070)
40. Bongartz T, Sutton AJ, Sweeting MJ, et al,. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85. (Pubitemid 43736578)
41. Askling J, Fored CM, Brandt L, et al,. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1421-6. (Pubitemid 41623851)
42. Wolfe F, Michaud K,. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007; 56: 2886-95. (Pubitemid 47502734)
43. Mariette X, Matucci-Cerinic M, Pavelka K, et al,. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011; 70: 1895-904.
44. Papatheodoridis GV, Hamilton M, Mistry PK, et al,. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 1998; 43: 639-44. (Pubitemid 28520097)
45. Ho GT, Seddon AJ, Therapondos G, et al,. The clinical course of ulcerative colitis after orthotopic liver transplantation for primary sclerosing cholangitis: further appraisal of immunosuppression post transplantation. Eur J Gastroenterol Hepatol 2005; 17: 1379-85. (Pubitemid 41830461)
46. Miki C, Harrison JD, Gunson BK, et al,. Inflammatory bowel disease in primary sclerosing cholangitis: an analysis of patients undergoing liver transplantation. Br J Surg 1995; 82: 1114-7.
47. Verdonk RC, Dijkstra G, Haagsma EB, et al,. Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am J Transplant 2006; 6: 1422-9. (Pubitemid 44030325)
48. Pan A, Schlup M, Lubcke R, et al,. Fulminant ulcerative colitis despite maximal immunosuppression following liver transplantation: a case report and literature review. J Crohns Colitis 2011; 5: 465-8.
49. Gavaler JS, Delemos B, Belle SH, et al,. Ulcerative colitis disease activity as subjectively assessed by patient completed questionnaires following orthotopic liver transplantation for sclerosing cholangitis. Dig Dis Sci 1991; 36: 321-8.
50. Befeler AS, Lissoos TW, Schiano TD, et al,. Clinical course and management of inflammatory bowel disease after liver transplantation. Transplantation 1998; 65: 393-6. (Pubitemid 28095969)
51. Wörns AW, Lohse MF, Neurath MF, et al,. Five cases of de novo inflammatory bowel disease after orthotopic liver transplantation. Am J Gastroenterol 2006; 101: 1931-7. (Pubitemid 44166606)
52. Barritt AS 4th, Zacks SL, Rubinas TC, et al,. Oral budesonide for the therapy of post-liver transplant de novo inflammatory bowel disease: a case series and systematic review of the literature. Inflamm Bowel Dis 2008; 14: 1695-700.